Given the clinical utility in fertility preservation counseling and for consideration of subsequent endocrine treatment approaches, the present analysis aimed at investigating the potential for AMH and other ovarian biomarkers to assess posttreatment long-term loss of ovarian function and its pretreatment prediction in premenopausal women with HER2-positive early breast cancer who participated in 2 large randomized controlled trials (RCTs) employing modern chemotherapy regimens and HER2-directed therapies. This evidence concerns the gene AMH and breast cancer.